NCT01337336View on ClinicalTrials.gov

Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population

CompletedOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

March 31, 2011

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

fluticasone propionate/salmeterol xinafoate

combination fluticasone priopionate and salmeterol xinafoate 250/50mcg

DRUG

Anticholinergics

tiotropium; ipratropium alone; or ipratropium + albuterol

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01337336 - Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population | Biotech Hunter | Biotech Hunter